OMNISCAN is the world’s first non-ionic MRI contrast agent and has been administered to over 40 million patients during the past 15 years.

It improves healthcare by helping diagnose disease earlier and showing treatments are working.

OMNISCAN is a gadolinium-based contrast agent for diagnostic magnetic resonance imaging (MRI) indicated for intravenous use to:

  • Visualize lesions with abnormal vascularity in the brain, spine, and associated tissues.
  • Facilitate the visualization of lesions with abnormal vascularity within the thoracic, abdominal, pelvic cavities, and the retroperitoneal space.